Project Grant R21AI196802
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $233K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $867,869 on June 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and validate small molecule metabolites in vaginal fluid as diagnostic biomarkers for bacterial vaginosis, trichomoniasis, and vulvovaginal candidiasis. The research addresses an unmet clinical need: current diagnostic approaches for vaginal discharge syndrome are either rapid and inexpensive...
- The National Institute of Allergy and Infectious Diseases awarded $264,750 to the University of Washington on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of three transcriptional regulators—DR1, DRAP1, and BTAF1—in suppressing interferon responses triggered by self-RNA ligands. The research characterizes how loss of these proteins induces robust interferon responses and explores the immunostimulatory double-stranded RNA...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded $902,741 to the University of Washington on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds basic research into the cell type-specific regulation of STING signaling, a central pathway in innate immune response with implications for antiviral immunity, antitumor immunity, and aging-associated inflammation. The research investigates why STING activation produces...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $777,498 to the University of Washington on May 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate the structural basis of parasteric inhibition mechanisms targeting bacterial adhesins, specifically the fimbrial lectin FimH of uropathogenic E. coli. The project characterizes how monoclonal antibodies and de novo-designed miniproteins...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $804,183 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to design bifunctional chimeric proteins that redirect immune responses against antibiotic-resistant bacterial pathogens. The project applies deep learning-enabled protein design to create bacterial targeting chimeras (BacTACs) that simultaneously bind surface proteins on antibiotic-resistant bacteria...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $191,268 on August 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the epigenetic architecture of autoimmune risk loci, with focus on multiple sclerosis and type 1 diabetes. The award funds research into noncoding genetic variants and their role in autoimmune disease susceptibility. The project uses long-read chromatin fiber sequencing techniques...
- The National Institute of Allergy and Infectious Diseases awarded the University of Maryland, Baltimore $427,625 on April 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to model the vaginal microbiome and predict bacterial vaginosis recurrence. The research applies metagenomic community state types to identify functionally distinct presentations of bacterial vaginosis and develop preventative interventions, addressing the high recurrence rates—60 percent at six...
- Federal Grant Award Summary Seattle University is receiving $511,763 in Project Grant funding from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a three-year project period beginning September 1, 2025 and concluding August 31, 2028. The award supports research to develop and apply activity-based protein profiling (ABPP), a chemical proteomics technique, to analyze molecular function within...
- The National Institute of Allergy and Infectious Diseases awarded $267,000 to the Benaroya Research Institute at Virginia Mason on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into circulating and mucosal immune cell populations affected by therapeutic interleukin-23 blockade in Crohn's disease patients treated with risankizumab. The project will quantify and characterize TH17 cells, mucosa-associated invariant T cells,...
- The National Institute of Allergy and Infectious Diseases awarded $886,942 to Benaroya Research Institute At Virginia Mason on June 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms of commensal-specific CD8+ T cell differentiation, restraint, and dysregulation in intestinal inflammation. The award supports research into how CD8+ intraepithelial lymphocytes respond to gut microbiota under homeostasis and become dysregulated in...